King Charles III was briefly hospitalized Thursday due to temporary side effects from ongoing cancer treatment, initially diagnosed in February 2024 following a procedure for benign prostate enlargement. His afternoon engagements were postponed, and Friday’s schedule was also rescheduled as a precaution. The King’s treatment is reportedly progressing positively. He expressed his apologies for any inconvenience caused by the cancellations.
Read More
Regence BlueCross BlueShield of Utah’s denial of coverage for the FDA-approved cancer drug Perjeta, prescribed by a specialist for a patient’s breast cancer treatment, exemplifies a critical flaw in the healthcare system. This denial contradicts established clinical guidelines and expert consensus, forcing the family to potentially shoulder over $160,000 in out-of-pocket costs. This case highlights how insurance companies obstruct access to necessary life-saving treatments, leaving patients in a precarious situation. The urgent need for systemic reform, including universal healthcare, is underscored by this and countless similar experiences.
Read More
John Q. Hosedrinker